| Turmerones — Turmerones are lipophilic volatile sesquiterpenes from turmeric rhizome oil, mainly ar-turmerone, α-turmerone, and β-turmerone. They are distinct from curcuminoids and should not be treated as curcumin synonyms. Formal classification: plant-derived volatile oil constituents / sesquiterpene ketones. Standard abbreviations include ATM or ar-T for aromatic turmerone, and α-TUR / β-TUR for α- and β-turmerone.
Separate database product from whole turmeric or curcumin, because turmerones have different PK, BBB penetration, P-gp modulation, and apoptosis mechanisms from curcumin.
Primary mechanisms (ranked):
- ROS-linked mitochondrial and death-receptor apoptosis, especially reported for ar-turmerone in hepatocellular carcinoma and leukemia models.
- Growth suppression and programmed cell death in selected cancer cell lines, with strongest support in preclinical leukemia and hepatocellular carcinoma studies.
- Migration and invasion suppression in glioma models through cathepsin B and P27-related signaling.
- Inflammation and stress-pathway modulation, including NF-κB, JNK, p38 MAPK, COX-2, iNOS, cytokines, and MMP-related axes, mostly context-dependent.
- Curcumin bioavailability and transporter modulation, including altered Caco-2 transport and mixed P-gp effects depending on the turmerone isomer.
Bioavailability / PK relevance: Turmerones are more lipophilic than curcumin and are relevant as turmeric-oil constituents and as curcumin bioavailability modifiers. Reported animal PK suggests measurable systemic exposure, moderate oral bioavailability for major turmeric-oil constituents, and meaningful brain distribution. Human therapeutic PK for isolated turmerones remains insufficient.
In-vitro vs systemic exposure relevance: Many anticancer experiments use tens of μg/mL concentrations, which may exceed typical achievable free systemic exposure after ordinary turmeric intake. Turmeric oil or enriched turmerone formulations may increase exposure, but cancer-cell IC50 values should be treated as preclinical screening concentrations rather than clinically validated dosing targets.
Clinical evidence status: Preclinical. There is no strong cancer clinical-trial evidence for isolated turmerones. Human turmeric oil safety data and curcumin/turmeric-formulation trials do not establish turmerone-specific oncology efficacy. Recommended database status: add as a separate mechanistic/preclinical product, linked to turmeric oil and curcumin as related entries.
Turmerones Cancer Mechanism Table
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Mitochondrial ROS apoptosis |
↑ ROS, ↓ mitochondrial membrane potential, ↑ Bax, ↑ PUMA, ↑ cytochrome c release, ↑ caspase-9, ↑ caspase-3 |
Likely lower selectivity margin not fully established |
R/G |
Apoptosis induction |
Core ar-turmerone mechanism in hepatocellular carcinoma models; high concentration only; model-dependent |
| 2 |
Death receptor apoptosis |
↑ Fas, ↑ DR4, ↑ caspase-8, ↑ caspase-3 |
Insufficient direct comparison |
R/G |
Extrinsic apoptosis support |
Appears coupled to ROS and MAPK stress signaling rather than a fully independent primary trigger |
| 3 |
JNK and ERK stress signaling |
↑ JNK, ↑ ERK, ↑ pro-apoptotic signaling |
Context-dependent |
R/G |
Amplifies apoptosis |
Stress-kinase activation appears downstream of ROS in hepatocellular carcinoma models |
| 4 |
Programmed cell death in leukemia |
↑ DNA fragmentation, ↑ apoptotic morphology, ↓ viability |
Some selectivity reported versus selected non-target cells, but evidence remains limited |
G |
Cytotoxic apoptosis |
Older but relevant evidence supports ar-turmerone and related turmeric-oil constituents as apoptosis inducers in leukemia models |
| 5 |
Glioma cathepsin B and P27 axis |
↓ cathepsin B, ↓ P27 cleavage, ↓ proliferation, ↓ mobility |
Not well defined |
G |
Reduced proliferation and migration |
Potential CNS-oncology relevance because ar-turmerone is brain-penetrant; still preclinical |
| 6 |
NF-κB inflammatory axis |
↔/↓ NF-κB depending on model and stimulus |
↓ NF-κB activation in inflammatory microglial models |
R/G |
Anti-inflammatory and context-dependent anticancer support |
curcuminoids suppress NF-κB more consistently than turmerones in some comparative studies |
| 7 |
COX-2 iNOS MMP inflammatory mediators |
↓ COX-2, ↓ MMP-related signaling (context-dependent) |
↓ iNOS, ↓ COX-2, ↓ MMP-9 in activated microglia |
G |
Reduced inflammatory mediator output |
More relevant to inflammation, tumor microenvironment, and AD than direct tumor killing |
| 8 |
P-gp and curcumin transport |
↔ P-gp activity depending on isomer; ↑ curcumin cellular transport in Caco-2 model |
↔ drug-transporter interaction risk |
R |
Bioavailability and drug-interaction modulation |
α-turmerone and ar-turmerone have different transporter effects; this is a key reason to keep turmerones separate from curcumin |
| 9 |
Chemosensitization |
Possible ↑ intracellular exposure of co-administered compounds through transporter effects |
Possible altered exposure to normal tissues |
R/G |
Unproven adjunct potential |
Mechanistically plausible but not clinically established for oncology; not a strong chemosensitizer |
| 10 |
Clinical Translation Constraint |
Preclinical activity often requires high μg/mL concentrations |
Oral oil safety appears better supported than isolated high-dose oncology use |
G |
Limits clinical confidence |
Major constraints are exposure, formulation, isomer composition, lack of isolated-turmerone cancer trials, and potential transporter-mediated interactions |
P:0–30 min R:30 min–3 hr G:>3 hr
|